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Abstract
Caring for older patients with breast cancer presents unique clinical considerations because of preexisting and competing
comorbidity, the potential for treatment-related toxicity, and the consequent impact on functional status. In the context of
the COVID-19 pandemic, treatment decision making for older patients is especially challenging and encourages us to refocus
our treatment priorities. While we work to avoid treatment delays and maintain therapeutic benefit, we also need to mini-
mize the risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposures, myelosuppression, general che-
motherapy toxicity, and functional decline. Herein, we propose multidisciplinary care considerations for the aging patient
with breast cancer, with the goal to promote a team-based, multidisciplinary treatment approach during the COVID-19 pan-
demic and beyond. These considerations remain relevant as we navigate the “new normal” for the approximately 30% of
breast cancer patients aged 70 years and older who are diagnosed in the United States annually and for the thousands of older
patients living with recurrent and/or metastatic disease.
Even during “normal” times, taking care of aging patients with
breast cancer, particularly those with competing comorbidities,
is challenging. In the era of the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), clinicians and patients now
face an extra layer of considerations. These unprecedented
issues touch all patients but are particularly daunting for older
patients with cancer who simultaneously face excessive risks of
death from COVID-19 (1–4). More than ever before, we must crit-
ically explore patients’ priorities while determining the optimal
sequence, intensity, frequency, and duration of their treat-
ments. Older women carry a preexisting risk for worse breast
cancer outcomes than their younger counterparts and are at
heightened risk for both undertreatment and overtreatment in
the context of the COVID-19 pandemic (5).
Each treatment we consider (other than perhaps hormonal
therapy) will result in some additional risk and potential expo-
sures for a patient (and the staff who interact with that patient)
while limiting our patients’ ability to implement the social
distancing that protects them. Even a straightforward breast
surgery necessitates patient exposures to preoperative, intrao-
perative, and postoperative hospital staff and equipment as
well as unquantifiable risks of anesthesia and periprocedure
ventilation. Breast surgeries, like all other surgeries, also limit
operating room availability, use personal protective equipment,
and distract hospital staff from other more potentially impor-
tant roles, which may stress facility and personnel resources.
Herein, we propose a multidisciplinary care framework
(Table 1) for the aging patient with breast cancer in efforts to
maintain optimal care while limiting undue risk from SARS-
CoV-2 during this extended epidemic. Although data on this vi-
rus and its impact on the geriatric oncology population remain
sparse, the treatment considerations discussed here are derived
from the limited data and position papers on management of
older adults with breast cancer and aging. These recommenda-
tions remain relevant as we navigate the “new normal” for the
approximately 30% of breast cancer patients aged 70 years and
older who are diagnosed in the United States annually and for
the thousands of older patients living with recurrent and/or
metastatic disease. As we begin to emerge from the acute
effects of the COVID-19 pandemic on the care of patients with
cancer, we need to reflect on what aspects of COVID-19–induced
decision making and treatment considerations are worth sus-
taining into the future.
Of note, although we often refer to aged 70 years and older as a
potential threshold for older patients throughout this manuscript
based on randomized controlled trials (RCTs) that often include
this age group in eligibility, our suggestions are relevant for any
patient with clinically significant comorbidity, poor functional sta-
tus, or advanced functional age, regardless of chronological age
(6,7). Treatments for patients of all ages should be considered in
the context of their underlying risk for cancer recurrence and ther-
apy options, anticipated life expectancy, frailty, and competing
risk of contracting and developing severe COVID-19.
Unfortunately, we have limited data, apart from age, of the full
spectrum of illnesses that place a woman at increased risk of
complications.
Hormone Receptor-Positive (HR1) HER2-
Tumors
Approximately 80% of women aged 70 years and older have
HRþHER2- disease. Fortunately, older patients—especially those
aged 70 years and older—with lower-risk HRþ disease have sev-
eral treatment options, given the long-term data that exist from
multiple RCTs in the local therapy setting. These minimization-
of-therapy practices include the omission of sentinel lymph
node biopsy (8–10), radiation (11–16), or even surgery in the set-
ting of hormonal therapy administration (17–21). Although local
treatment omission has historically had variable uptake in clini-
cal practice (22–25), these strategies should be reconsidered in
the COVID-19 era and beyond because they do not compromise
outcomes. In particular, the data for radiation omission are ro-
bust and can likely be extrapolated to those with larger tumors
after multidisciplinary discussion. However, if radiation is pur-
sued after breast conservation or mastectomy, hypofractio-
nated schedules are encouraged whenever appropriate (26–28),
and it may be reasonable to delay the initiation of adjuvant ra-
diotherapy up to 12–20 weeks from the time of surgery and
12 weeks from last chemotherapy (29).
To reduce resource utilization, including staffing, equip-
ment, and supplies, in the operating room and to minimize
risks of hospital-acquired COVID-19 infection, initiation of pre-
operative hormonal therapy and delay of surgery are routinely
being adopted nationwide, particularly in regions of high SARS-
CoV-2 prevalence. Preoperative hormonal therapy can be initi-
ated not only in locally advanced disease, where up to 6 months
of therapy is considered within standard of care, but also in the
setting of early-stage disease. Primary hormonal therapy in the
setting of low-risk disease and in lieu of surgery as the initial
treatment also remains an option for older patients and has
demonstrated efficacy in multiple prospective, randomized
studies for patients aged 70 years and older (17–21). Hormonal
therapy, in general, provides a unique opportunity to defer
Table 1. General considerations for the patient aged 70 years and older with breast cancer during the COVID-19 pandemic and beyonda
Disease setting Treatment considerationsa
Lower-risk HRþ HER2- cancers • Consider options for (a) primary hormonal therapy; (b) BCS and hormonal therapy; or (c)
BCS, radiation, and hormonal therapy
• Consider hypofractionation whenever possible if radiation is administered
• Avoid sentinel lymph node biopsies for those with low-risk disease
• Consider neoadjuvant hormonal therapy in any patient with locally advanced disease
and/or those awaiting breast surgery
Higher-risk HRþHER2- disease • Use genomic profile testing to confirm chemotherapy benefit
• Select and modify any neo/adjuvant chemotherapy regimens and supportive medica-
tions to minimize immunosuppressionb
Triple-negative disease • Limit use of neo/adjuvant chemotherapy in small tumors
• Select and modify any neo/adjuvant chemotherapy regimens and supportive medica-
tions to minimize immunosuppressionb
HER2þ disease • Limit use of neo/adjuvant chemotherapy in small tumors
• Use hormonal therapy when also HRþ
• Select and modify any neo/adjuvant chemotherapy regimens and supportive medica-
tions to minimize immunosuppressionb
• Consider T-DM1, T-DM1 plus pertuzumab, or weekly paclitaxel-trastuzumab (þ/-) pertu-
zumab if neo/adjuvant treatment required
• Consider cessation of trastuzumab before 1 year when appropriate or use of subcutane-
ous administration to limit infusion time
Metastatic disease • Discuss goals of care
• Consider postponement of or dose-reduced cyclin-dependent kinase 4,6 inhibition until
COVID-19 exposure risks decline
• Consider oral therapy when appropriate (ie, capecitabine)
• Select and modify any neo/adjuvant chemotherapy regimens and supportive medica-
tions to minimize immunosuppressionb
aAlways consider patient priorities, preferences, concerns, competing comorbidity, life expectancy, frailty, and functional status in decision making; discuss antici-
pated benefits and harms of treatments. BCS ¼ breat conservation; HRþ ¼ hormone-receptor-positive; (T-DM1) ¼ ado-trastuzumab emtansine.
bSuch as limiting steroid use, using growth factor, avoiding anthracyclines, and modifying sequence of therapy.
further decision making on surgery (and other adjuvant care)
without compromising immunity and can be routinely explored
as upfront therapy while SARS-CoV-2 concerns are high. While
patients receive preoperative therapy, physical exams and/or
breast imaging should continue but can happen at more ex-
tended intervals, such as every 2–3 months, and compliance
with treatment should be assessed. As hospitals begin to reopen
their operating rooms because of declining numbers of patients
with COVID-19, risks for infection will remain on the forefront,
and queues for surgical care will be an intermittent reality.
In general, the use of neoadjuvant or adjuvant chemotherapy
in the older patient with HRþHER2- disease should be reserved for
the patients with the highest-risk cancers, given the anticipated
traditional and COVID-19–related risks and limited-to-modest
treatment benefit for the vast majority of patients. If chemother-
apy is being considered, we strongly suggest use of genomic profile
testing such as Oncotype DX. This can be informative at the time
of biopsy if preoperative therapy is being considered, even in
node-positive disease (30,31), to ensure clinical benefit. We suggest
an Oncotype score of greater than 30 as a potential threshold to
consider chemotherapy given the lack of clearly defined benefits
for older patients with scores of 26–30. In the preoperative setting,
hormonal therapy can be initiated even if chemotherapy is later
desired, once COVID-19 risks decline. If chemotherapy is pursued
postoperatively and concerns for COVID-19 remain high, postpon-
ing treatment initiation can be considered, given that associations
of chemotherapy delay and detrimental outcomes are not present
for most HRþHER2- cancers (32–34).
Although chemotherapy regimens should be individualized,
general strategies can be applied to limit myelosuppression,
minimize visit frequency, and avoid the need for anthracyclines
and steroids. We also suggest universal use of growth factor
support to minimize myelosuppression, febrile neutropenia,
and hospitalization risk. Standard regimens such as docetaxel
and cyclophosphamide (TC) are generally preferred.
Alternatively, a modified TC regimen (35–38)—currently being
explored in a clinical trial for patients aged 70 years and older
(NCT03858322) with use of paclitaxel (as an alternative to doce-
taxel) plus cyclophosphamide—may also be an option. It is
noteworthy that in the Anthracyclines in Early Breast Cancer
trial, standard TC  6 cycles was equivalent to anthracycline-
taxane–based regimens except when nodal disease burden was
high (39). In one small study (40), dose-dense cyclophospha-
mide-methotrexate-fluorouracil with growth factor support has
also emerged as a potential option for patients who need che-
motherapy because of the lack of severe neutropenia.
In patients with the highest-risk breast cancers, where an
anthracycline is felt to be an important component of therapy,
one can also consider sequential therapy as per the Cancer and
Leukemia Group B 9741 trial (41). In this study, the sequential
regimen was as efficacious as dose-dense combination therapy
and included every 2-week doxorubicin (A)  4 cycles followed
by paclitaxel (T)  4 cycles, followed by cyclophosphamide (C)
with growth factor support. However, in this case, one might
consider postponement of the anthracycline portion of therapy
until after the T-C or T alone (ie, upfront paclitaxel) to minimize
the immediate myelosuppression and cardiomyopathy risk.
Triple-Negative (TN) Tumors
Treatment modifications in the minority (10%) of older women
who have TN breast cancer may be less feasible and will require
more extensive multidisciplinary collaboration. For those with
clinical stage I or even stage II disease who are breast-
conserving candidates at baseline, a multidisciplinary team
should determine the optimal sequence of surgical, radiation,
and systemic treatments. If a postponement in surgery is neces-
sary or in the setting of locally advanced disease, one can con-
sider chemotherapy with one of the regimens previously
discussed. Weekly carboplatin-paclitaxel with deferment or
omission of anthracycline is also a chemotherapeutic option in
the preoperative or postoperative setting (42,43). However, we
recommend against chemotherapy for the majority of patients
with stage I TN disease, given the small absolute benefits and
the added risk for complications if SARS-CoV-2 infection occurs.
Evidence does not support the omission of procedures such as
radiation and node assessment even in lower-risk TN disease,
although multidisciplinary conversations on the anticipated
risks and benefits of these procedures and the associated expo-
sures will help determine the best course of action.
HER21 Tumors
In the approximately 10% of older breast cancer patients who
are diagnosed with HER2þ tumors, there are also treatment
modifications to consider. Because half of these patients will
also have HRþ disease, hormonal therapy remains a treatment
on its own in the setting of small tumors and frailty. Hormonal
therapy could also be considered in combination with HER2-
directed therapy without chemotherapy. In the case of HR-
HER2þ disease where HER2-directed therapy is desired, preop-
erative and postoperative treatment with nonmyelosuppressive
agents may be preferred at this time. Evidence-based, effica-
cious options include ado-trastuzumab emtansine (T-DM1) (44)
or T-DM1 plus pertuzumab, which is well tolerated and can be
highly effective, particularly in patients with HER2 immunohis-
tochemistry 3þ disease (45).
Although the RESPECT trial evaluated adjuvant trastuzumab
monotherapy vs trastuzumab plus physician choice chemother-
apy in patients 70–80 years of age (46), this study demonstrated
a nonstatistically significant, worse disease-free survival for the
trastuzumab-only arm. This trial did not include a no-
treatment arm to ascertain the impact of trastuzumab, and thus
its applicability in this setting is limited. We also recommend
avoidance or postponement of anthracyclines or carboplatin-
based regimens. Other ways of minimizing exposure to SARS-
CoV-2 for those on the maintenance portion of trastuzumab is
subcutaneous trastuzumab or the consideration of cessation of
maintenance therapy after 6 months given the limited differen-
ces in outcomes for those receiving 6 vs 12 months of trastuzu-
mab in 2 large RCTs (47,48). Omission of radiation in selected
situations for those receiving anti-HER2 therapy may also be
considered given the low locoregional risk for these patients.
Metastatic Disease
As always, the degree of palliation in the metastatic disease set-
ting should be dictated by the symptoms, disease burden, and
disease subtype. In the HRþ setting when symptom burden is
low, oral hormonal monotherapy is appropriate, with defer-
ment of cyclin-dependent kinase 4,6 inhibition in most patients
until the risks from COVID-19 are lowered. However, continua-
tion of previously beneficial and well-tolerated therapy of any
kind is reasonable but perhaps with decreased frequency of vis-
its, more virtual visits, and/or dose reductions or cessation of
cyclin-dependent kinase 4,6 inhibitors in the short term. When
chemotherapy is necessary across all disease subtypes, selec-
tion of regimens with consideration of comorbidity, frailty, life
expectancy, toxicity, patient preference, and quality of life is
warranted, with preferences for lower-intensity oral regimens
such as capecitabine. Upfront dose reductions in noncurative
intent settings can also be considered to minimize toxicity in
older patients. In the HER2þ disease setting, there are options
to modify treatment schedules, avoid myelosuppressive che-
motherapy, or implement drug holidays, particularly for those
with long-standing and well-controlled disease. Treatment
decisions in the metastatic setting will always remain highly in-
dividualized, although the threat of COVID-19 in this vulnerable
population should encourage discussions—which typically take
place at a later time—on goals of care, completion of advance
directives, avoidance of hospitalizations whenever necessary,
and hospice when appropriate.
Follow-up and Surveillance
Given the absence of proven benefit for annual, routine mam-
mography in the aging patient with comorbidity (49) and the ar-
bitrary intervals for follow-up care and examination, all routine
follow-up and breast imaging in the absence of symptoms can
be deferred for the time being to minimize unnecessary patient
and staff exposures (50). We anticipate this postponement of
breast imaging will spur discussions on the limited utility of
surveillance mammography that reach beyond the pandemic,
with an increased awareness that routine mammography has
low value in patients with limited life expectancy and compet-
ing comorbidity.
Studying the Impact of COVID-19 on Older
Patients With Cancer
Understanding the impact of COVID-19 on older adults with
cancer will require coordinated multicenter collaboration to
study both infected and uninfected aging patients who were
treated during the pandemic. Decision making, treatment pat-
terns, and outcomes (cancer related and COVID-19 related) will
need to be studied, and a consensus on the treatment modifica-
tions we want to take forward into the post–COVID-19 era will
need to be reached. There will be important details to analyze
in these data, particularly for those infected with SARS-CoV-2,
including the types of treatments patients were receiving and
how community-dwelling and hospitalized patients fared.
Some relevant efforts are now underway, led in part by the
Cancer and Aging Research Group and others, which will work
to establish an evidence base in this context. However, more
efforts are needed to integrate geriatric-guided approaches in
ongoing efforts to understand the clinical and biological impli-
cations of SARS-CoV-2 infections in older adults with cancer.
In summary, the COVID-19 pandemic has reinforced the pre-
existing importance of the multidisciplinary, patient-centered
approaches when caring for aging patients with breast cancer.
In addition, treatment decisions must now consider our public
health threats, including the health of medical staff and ade-
quacy of resources. Even as the numbers of COVID-19 cases de-
cline in some regions, we are now facing a new normal for older
adults who remain at a protracted risk for infection. Efforts to
minimize immunosuppression and potential COVID-19 expo-
sures will remain crucial, as will the lessons we have learned
with regard to resource allocation and patient preferences.
As always, there is power and comfort in reassurance and
clear messaging to patients and their loved ones when creating
treatment plans, advising them of our concerns, and including
them in the conversation. If patients understand that we are
trying not to compromise benefits when we modify treatment
plans, they will appreciate our goals to keep them home, safe,
well, socially distanced, and with as intact an immunity as pos-
sible. In the end, there are many lessons to take with us into the
post–COVID-19 era. If nothing else, as an oncology workforce,
we will be stronger, more agile, adaptable, appreciative, and
thoughtful in our approach to care than ever before.
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